EmVenio Clinical Research: Unifying Multiple Brands to Enhance Clinical Trial Accessibility
In a significant move to innovate and enhance clinical trial accessibility, PCM Trials has rebranded alongside its subsidiaries, EmVenio Research and Clinical Trial Service, all now operating under the unified name of EmVenio Clinical Research. This strategic consolidation aims to leverage the collective strengths of each company to better serve sponsors and contract research organizations (CROs) with improved flexibility and a broader global reach.
The transition to EmVenio Clinical Research marks a new chapter for the company, which is a division of Professional Case Management (PCM). This new identity is not just a name change; it represents a commitment to making clinical research more accessible and participant-friendly. As Greg Austin, the president of PCM Trials and now EmVenio Clinical Research, stated, this branding consolidation will become a new industry standard in community clinical research, enhancing both participant enrollment and retention in studies conducted across North America, Europe, and beyond.
By unifying these previously distinct organizations, EmVenio is poised to offer a robust platform of solutions that streamline patient accessibility and engagement in clinical trials. The EmVenio brand is already operational in over 80 countries, utilizing mobile teams and local research centers to engage potential study participants in their own communities. This is particularly beneficial because it allows research to be conducted where participants live and work, opening doors that traditional barriers have kept closed.
Additionally, EmVenio is launching a new initiative called Patient Navigator™. This tailored support service is designed to eliminate logistical and financial hurdles that often deter patients from participating in clinical trials. It is especially critical for therapeutic areas that can be burdensome for participants, such as rare diseases and pediatrics. The Patient Navigator service promises a flexible approach, including travel coordination, accommodation arrangements, reimbursement assistance, as well as other EmVenio services like remote, virtual, and community-based visits. The overarching objective is to make participation in clinical trials more attainable than ever.
Founded in 2008, PCM Trials quickly became a leader in decentralized clinical trials, specializing in mobile nursing visits to participants' homes. Many innovations introduced by PCM Trials are now standard practices within the clinical research community. With the acquisitions of Clinical Trials Service and EmVenio Research, PCM has forged a powerful alliance focused on expanding global access to essential clinical trials.
EmVenio Clinical Research, with its headquarters based in the United States and Europe, boasts an expert workforce of approximately 5,000 professionals dedicated to supporting high-quality, efficient clinical studies. This includes creating a diverse patient recruitment strategy, boasting over 75% of enrolled participants belonging to minority groups and achieving retention rates exceeding 92% across various trials.
This newly unified brand embodies the vision for a future of clinical research that resonates with accessibility and participant empowerment. The choice of the name “EmVenio” draws from the Latin 'venio', meaning 'to reach', which underscores their strategic aim to connect with patients in ways that traditional models often overlook. The commitment to empathy, expertise, and strong partnerships reinforces their mission to bridge the gap between scientific research and real-world applications for health.— thus, advancing the whole field of clinical medicine. For more information about EmVenio Clinical Research, visit their website at emvenio.com.
The transition to EmVenio Clinical Research marks a new chapter for the company, which is a division of Professional Case Management (PCM). This new identity is not just a name change; it represents a commitment to making clinical research more accessible and participant-friendly. As Greg Austin, the president of PCM Trials and now EmVenio Clinical Research, stated, this branding consolidation will become a new industry standard in community clinical research, enhancing both participant enrollment and retention in studies conducted across North America, Europe, and beyond.
By unifying these previously distinct organizations, EmVenio is poised to offer a robust platform of solutions that streamline patient accessibility and engagement in clinical trials. The EmVenio brand is already operational in over 80 countries, utilizing mobile teams and local research centers to engage potential study participants in their own communities. This is particularly beneficial because it allows research to be conducted where participants live and work, opening doors that traditional barriers have kept closed.
Additionally, EmVenio is launching a new initiative called Patient Navigator™. This tailored support service is designed to eliminate logistical and financial hurdles that often deter patients from participating in clinical trials. It is especially critical for therapeutic areas that can be burdensome for participants, such as rare diseases and pediatrics. The Patient Navigator service promises a flexible approach, including travel coordination, accommodation arrangements, reimbursement assistance, as well as other EmVenio services like remote, virtual, and community-based visits. The overarching objective is to make participation in clinical trials more attainable than ever.
Founded in 2008, PCM Trials quickly became a leader in decentralized clinical trials, specializing in mobile nursing visits to participants' homes. Many innovations introduced by PCM Trials are now standard practices within the clinical research community. With the acquisitions of Clinical Trials Service and EmVenio Research, PCM has forged a powerful alliance focused on expanding global access to essential clinical trials.
EmVenio Clinical Research, with its headquarters based in the United States and Europe, boasts an expert workforce of approximately 5,000 professionals dedicated to supporting high-quality, efficient clinical studies. This includes creating a diverse patient recruitment strategy, boasting over 75% of enrolled participants belonging to minority groups and achieving retention rates exceeding 92% across various trials.
This newly unified brand embodies the vision for a future of clinical research that resonates with accessibility and participant empowerment. The choice of the name “EmVenio” draws from the Latin 'venio', meaning 'to reach', which underscores their strategic aim to connect with patients in ways that traditional models often overlook. The commitment to empathy, expertise, and strong partnerships reinforces their mission to bridge the gap between scientific research and real-world applications for health.— thus, advancing the whole field of clinical medicine. For more information about EmVenio Clinical Research, visit their website at emvenio.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.